news

CUPERTINO, Calif., Oct. 14 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical company announced today the initiation of dosing for the Phase III clinical studies for the DURIN(TM)-based leuprolide program under development with Voyager Pharmaceuticals for the treatment of Alzheimer’s disease (the Memryte(TM) implant). “We are delighted to meet this significant milestone in […]

CUPERTINO, Calif., Oct. 13 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2005. DURECT’s net loss for the three months ended September 30, 2005 was $3.0 million or 6 cents per share, compared to a net loss of $7.3 million or 14 cents per share for

CUPERTINO, Calif., Oct 07, 2005 /PRNewswire-FirstCall via COMTEX News Network/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter 2005 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, October 13, 2005 at 4:30 p.m. EDT. What: DURECT Corporation’s Third

CUPERTINO, Calif., Sept 21, 2005 /PRNewswire-FirstCall via COMTEX News Network/ — DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical company, announced today it plans to present preliminary cohort 3 clinical data from its Phase II study for DURECT’s post-operative pain relief depot, SABER(TM)-Bupivacaine, during the American College of Surgeons Conference in San Francisco, CA, October

CUPERTINO, Calif., Sept. 19 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX – News), an emerging specialty pharmaceutical company, announced today the completion of dosing in the third and final cohort of the Phase II dose escalation study in hernia patients in Australia for DURECT’s post-operative pain relief depot, SABER(TM)-Bupivacaine. The Company completed enrollment of approximately 60

CUPERTINO, Calif., Sept. 9 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical company, announced today that Pain Therapeutics, Inc. has achieved positive Phase III clinical results for Remoxy(TM), a novel long-acting, abuse-deterrent oral formulation of oxycodone based on DURECT’s ORADUR(TM) technology being developed under license from DURECT. “These results represent a significant milestone

CUPERTINO, Calif., Aug. 8 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Summer Tech Fest 2005 Investor Conference Hosted by C.E. Unterberg Towbin and Security Research Associates. The conference is being held at the Omni Hotel in San Francisco. Felix Theeuwes, D.Sc., Chairman and Chief Scientific Officer, will be

CUPERTINO, Calif., Aug. 1 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Adams, Harkness & Hill Annual Summer Seminar. The conference is being held at the Boston Marriott Long Wharf Hotel. James E. Brown, DVM, President and Chief Executive Officer, will be presenting at the conference on Wednesday, August

CUPERTINO, Calif., July 22 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2005. DURECT’s net loss for the three months ended June 30, 2005 was $3.6 million or 7 cents per share, compared to a net loss of $7.4 million or 14 cents per share for

CUPERTINO, Calif., July 22 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that the Company has entered into a privately negotiated agreement with a holder of its 6.25% Convertible Subordinated Notes, due June 2008, to exchange up to $5 million in principal amount of convertible notes for 317.4603 shares of common stock per $1,000 principal